参考文献/References:
［1］ DEVERGNE O,BIRKENBACH M,KIEFF E.Epstein-Barr virus-induced gene 3 and the p35 subunit of interleukin 12 form a novel heterodimeric hematopoietin ［J］.Proc Natl Acad Sci U S A,1997,94(22):12041-12046.
［2］ DEVERGNE O,HUMMEL M,KOEPPEN H,LE BEAU M M,NATHANSON E C,KIEFF E,et al.A novel interleukin-12 p40-related protein induced by latent Epstein-Barr virus infection in B lymphocytes ［J］.J Virol,1996,70(2):1143-1153.
［3］ SCHRADER J W.Interleukin is as interleukin does ［J］.J Immunol Methods,2003,276(1/2):1-3.
［4］ OPPMANN B,LESLEY R,BLOM B,TIMANS J C,XU Y,HUNTE B,et al.Novel p19 protein engages IL-12p40 to form a cytokine,IL-23,with biological activities similar as well as distinct from IL-12 ［J］.Immunity,2000,13(5):715-725.
［5］ PFLANZ S,TIMANS J C,CHEUNG J,ROSALES R,KANZLER H,GILBERT J,et al.IL-27,a heterodimeric cytokine composed of EBI3 and p28 protein,induces proliferation of naive CD4+ T cells ［J］.Immunity,2002,16(6):779-790.
［6］ VIGNALI D A,KUCHROO V K.IL-12 family cytokines:immunological playmakers ［J］.Nat Immunol,2012,13(8):722-728.
［7］ COLLISON L W,WORKMAN C J,KUO T T,BOYD K,WANG Y,VIGNALI K M,et al.The inhibitory cytokine IL-35 contributes to regulatory T-cell function ［J］.Nature,2007,450(7169):566-569.
［8］ COLLISON L W,DELGOFFE G M,GUY C S,VIGNALI K M,CHATURVEDI V,FAIRWEATHER D,et al.The composition and signaling of the IL-35 receptor are unconventional ［J］.Nat Immunol,2012,13(3):290-299.
［9］ SILVER J S,HUNTER C A.GP130 at the nexus of inflammation,autoimmunity,and cancer ［J］.J Leukoc Biol,2010,88(6):1145-1156.
［10］ WANG R X,YU C R,DAMBUZA I M,MAHDI R M,DOLINSKA M B,SERGEEV Y V,et al.Interleukin-35 induces regulatory B cells that suppress autoimmune disease ［J］.Nat Med,2014,20(6):633-641.
［11］ 张宇,沈雪,吴青青,方宗宇,马莉.强直性脊柱炎患者血清IL-35、IL-17水平变化及其临床意义 ［J］.山东医药， 2020,60(9):67-69.
ZHANG Y,SHEN X,WU Q Q,FANG Z Y,MA L.Changes of serum IL-35 and IL-17 levels in patients with ankylosing spondylitis and their clinical significance［J］.Shandong Med,2020,60(9):67-69.
［12］ YE Z,JIANG Y,SUN D,ZHONG W,ZHAO L,JIANG Z.The plasma interleukin(IL)-35 level and frequency of circulating IL-35(+) regulatory B cells are decreased in a cohort of Chinese patients with new-onset systemic lupus erythematosus ［J］.Sci Rep,2019,9(1):13210.
［13］ XU R,SHEARS R K,SHARMA R,KRISHNA M,WEBB C,ALI R,et al.IL-35 is critical in suppressing superantigenic staphylococcus aureus-driven inflammatory Th17 responses in human nasopharynx-associated lymphoid tissue ［J］.Mucosal Immunol,2020,13(3):460-470.
［14］ YANG H,HAN L,ZHOU Y J,DING J,CAI Y,HONG R H,et al.Lower serum interleukin-22 and interleukin-35 levels are associated with disease status in neuromyelitis optica spectrum disorders ［J］.CNS Neurosci Ther,2020,26(2):251-259.
［15］ ZHANG J,LIN Y,LI C,ZHANG X,CHENG L,DAI L,et al.IL-35 decelerates the inflammatory process by regulating inflammatory cytokine secretion and M1/M2 macrophage ratio in psoriasis ［J］.J Immunol,2016,197(6):2131-2144.
［16］ ZHAO M M,SONG J C,DU S S,ZHANG Y,ZHOU Y,LI Q H,et al.Serum IL-35 levels are associated with activity and progression of sarcoidosis ［J］.Front Immunol,2020,11:977.
［17］ LIAN M,ZHANG J,ZHAO L,CHEN X,PENG Y,WANG Q,et al.Interleukin-35 regulates immune microenvironment of autoimmune hepatitis through inducing the expansion of myeloid-derived suppressor cells ［J］.Front Immunol,2019,10:2577.
［18］ ITO T,TANAKA T,NAKAMARU K,TOMIYAMA T,YAMAGUCHI T,ANDO Y,et al.Interleukin-35 promotes the differentiation of regulatory T cells and suppresses Th2 response in IgG4-related type 1 autoimmune pancreatitis ［J］.J Gastroenterol,2020,55(8):789-799.
［19］ LIU M X,LIU Q Y,LIU Y,CHENG Z M,LIU L,ZHANG L,et al.Interleukin-35 suppresses antitumor activity of circulating CD8(+) T cells in osteosarcoma patients ［J］.Connect Tissue Res,2019,60(4):367-375.
［20］ SAWANT D V,YANO H,CHIKINA M,ZHANG Q,LIAO M,LIU C,et al.Adaptive plasticity of IL-10(+) and IL-35(+) T(reg) cells cooperatively promotes tumor T cell exhaustion ［J］.Nat Immunol,2019,20(6):724-735.
［21］ YANG L,SHAO X,JIA S,ZHANG Q,JIN Z.Interleukin-35 dampens CD8(+) T cells activity in patients with non-viral hepatitis-related hepatocellular carcinoma ［J］.Front Immunol,2019,10:1032.
［22］ TAKEDA A,HASEGAWA E,NAKAO S,ISHIKAWA K,MURAKAMI Y,HISATOMI T,et al.Vitreous levels of interleukin-35 as a prognostic factor in B-cell vitreoretinal lymphoma ［J］.Sci Rep,2020,10(1):15715.
［23］ DAMBUZA I M,HE C,CHOI J K,YU C R,WANG R,MATTAPALLIL M J,et al.IL-12p35 induces expansion of IL-10 and IL-35-expressing regulatory B cells and ameliorates autoimmune disease ［J］.Nat Commun,2017,8(1):719.
［24］ TAKEDA A,HASEGAWA E,FUKUHARA T,HIRAKAWA S,YAMADA H,YANG Y,et al.EBI3 is pivotal for the initiation of experimental autoimmune uveitis ［J］.Exp Eye Res,2014,125:107-113.
［25］ KANG M,CHOI J K,JITTAYASOTHORN Y,EGWUAGU C E.Interleukin 35-producing exosomes suppress neuroinflammation and autoimmune uveitis ［J］.Front Immunol,2020,11:1051.
［26］ YU C R,CHOI J K,UCHE A N,EGWUAGU C E.Production of IL-35 by bregs is mediated through binding of BATF-IRF-4-IRF-8 complex to IL12a and EBI3 promoter elements ［J］.J Leukoc Biol,2018,104(6):1147-1157.
［27］ HU J,QIN Y,YI S,WANG C,YANG J,YANG L,et al.Decreased interleukin(IL)-35 expression is associated with active intraocular inflammation in Vogt-Koyanagi-Harada(VKH) disease ［J］.Ocul Immunol Inflamm,2019,27(4):595-601.
［28］ YONG C,DAN L,CHENHONG L,YAN S,JIANFEI C,JIANLONG G.Efficacy and safety of metformin for Behcet’s disease and its effect on Treg/th17 balance:a single-blinded,before-after study［J］.Nanfang Yike Daxue Xuebao,2019,39(2):127-133.
［29］ LOPALCO G,LUCHERINI O M,LOPALCO A,VENERITO V,FABIANI C,FREDIANI B,et al.Cytokine signatures in mucocutaneous and ocular Behcet’s disease ［J］.Front Immunol,2017,8:200.
［30］ SONMEZ C,YUCEL A A,YESIL T H,KUCUK H,SEZGIN B,MERCAN R,et al.Correlation between IL-17A/F,IL-23,IL-35 and IL-12/-23(p40) levels in peripheral blood lymphocyte cultures and disease activity in Behcet’s patients ［J］.Clin Rheumatol,2018,37(10):2797-2804.